WuXi XDC Cayman Inc (2268.HK)

Healthcare | Medical Diagnostics Research
Latest reporting period: 2026-04-07

Latest Quarter

2026-04-07

Revenue

$2.7B

Net Income

$746M

Operating Margin

28.4%

Free Cash Flow

-$788M

Debt / Assets

25.7%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for WuXi XDC Cayman Inc (2268.HK).
Income Statement (Quarterly) 2026-04-07 2025-12-31 2025-06-30 2025-03-31
Revenue 2,700,869,000 3,189,264,865 2,700,869,000 1,350,434,500
Cost of Revenue 1,725,622,000 2,044,609,824 1,725,622,000 862,811,000
Gross Profit 975,247,000 1,144,655,040 975,247,000 487,623,500
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 158,835,000 209,033,403 158,835,000 79,417,500
Operating Expenses 208,318,000 305,130,950 208,318,000 104,159,000
Operating Income 766,929,000 839,524,089 766,929,000 383,464,500
Interest Expense 0 9,137,958 0 0
Income Before Tax 867,150,000 854,970,023 867,150,000 433,575,000
Income Tax Expense 121,449,000 132,434,038 121,449,000 60,724,500
Net Income 745,701,000 722,535,985 745,701,000 372,850,500
Per Share
EPS 0.62 0.58 0.62 0.31
EPS Diluted 0.00 0.00 0.00 0.00